Coulter Partners places Dr. David Rosenbaum as Chief Development Officer of Syntis Bio
BOSTON, MA and LONDON, UK – March 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Syntis Bio, Inc. and is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO).
Syntis Bio is a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine to treat obesity and rare metabolic diseases. As CDO, Dr. Rosenbaum will oversee the company’s clinical and technical development capabilities and the advancement of the pipeline through critical development and regulatory milestones.
Dr. Rosenbaum brings more than 20 years of experience in clinical development and regulatory strategy, with a distinguished track record of guiding gastrointestinal and metabolic therapies from first-in-human studies through to FDA approval. He most recently served as Chief Development Officer at Ardelyx, where he successfully led the development and registration of Xphozah® and Ibsrela®.
Rahul Dhanda, Chief Executive Officer of Syntis Bio, commented: “David joins us at a transformative time as we advance our lead program, SYNT-101, into the clinic. His deep expertise in drug development and his proven ability to drive programs from idea through clinical studies and to the patient will be invaluable as we expand our technical capabilities.
“We truly appreciated the partnership and strategic guidance provided by Coulter Partners throughout this process. They understood that for Syntis to unlock the therapeutic potential of the small intestine, we needed a leader who not only understands the science but also has the operational experience to advance our pipeline through critical regulatory milestones.”
Chris Palatucci, Client Partner at Coulter Partners, added: “It was a privilege to partner with Rahul and the board on this pivotal search. Coulter Partners specializes in identifying leadership for frontier science where the path to market is complex. Placing high-caliber Chief Development Officers is at the heart of what we do, and David is a rare talent who bridges the gap between groundbreaking research and regulatory execution. He is the ideal leader to help Syntis Bio bring these transformative therapies to patients.”
—
Dr. David Rosenbaum, Ph.D., Chief Development Officer at Syntis Bio.
Dr. Rosenbaum brings more than two decades of experience in clinical development and regulatory strategy across gastrointestinal, metabolic and cardiovascular diseases.
Prior to joining Syntis Bio, he served as Chief Development Officer at Ardelyx, where he led development efforts for multiple programs. Most notably, he guided Xphozah® and Ibsrela® through FDA approval for the treatment of hyperphosphatemia in chronic kidney disease and irritable bowel syndrome with constipation, respectively. Earlier in his career, Dr. Rosenbaum held senior development roles at Fenway Pharmaceuticals, Trine Pharmaceuticals, Phaedrus Pharmaceuticals and GelTex Pharmaceuticals, where he advanced small-molecule and non-systemic therapeutics from first-in-human studies through late-stage development and registration, building a track record of disciplined execution in high-unmet-need indications.
Dr. Rosenbaum holds a Ph.D. in Pharmacology from Boston University School of Medicine, an M.S. in Toxicology from Albany Medical College and a B.A. in Biology from the University of Pennsylvania.
[ENDS]
Notes to editors:
About Syntis Bio
Syntis Bio is a clinical-stage biopharmaceutical company with a growing pipeline across obesity and rare disease. The company is currently enrolling a Phase 1/1b clinical study to evaluate lead program SYNT-101 in obesity. Syntis Bio’s pill-based synthetic tissue platform unlocks the therapeutic potential of the small intestine by creating a safe, tolerable and temporary lining that allows precise, programmable control of both nutrient and drug absorption. Syntis Bio is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. Alongside SYNT-101, the company is advancing a portfolio of therapies in obesity and in orphan metabolic diseases. Syntis Bio is headquartered in Boston, MA.
For more information, please visit www.syntis.bio
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
